Journal of Antimicrobial Chemotherapy (1994) 34, 659-668
© 1994 The British Society for Antimicrobial Chemotherapy
research-article |
High prevalence of antifungal resistance in Candida spp. from patients with AIDS
aDepartments of Microbiology and Medicine, University of Manchester, Hope Hospital Eccles Old Road, Salford M6 8HD; UK bDepartment of Infectious Diseases and Tropical Medicine, North Manchester General Hospital Delaunays Road, Manchester M8 6RL, UK
Received 17 December 1993; accepted 2 August 1994
*Corresponding author.
Three hundred and forty-eight isolates of Candida spp. from patients treated at a regional infectious diseases unit for AIDS, immunocompromised patients admitted to the Hope Hospital and isolates referred from around the North West of England were tested for their in-vitro susceptibility to amphoteriein B, fluconazole and flucytosine using standardized methods. Candida albicans comprised 73% of isolates, Candida glabrata 10% and Candida parapsilosis 7%. Ninety-six percent of isolates were susceptible to amphotericin B and resistance to 
12.5 mg/L fluconazole was found in 61 (17.5%) of the 348 isolates tested. Among isolates from patients with AIDS the incidence of fluconazole resistance was 33% whereas in other patients the incidence was only 11%. Flucytosine resistance was seen in only 12 (3.4%) isolates, 11 of which were C. albicans and in 6.5% of isolates from patients with AIDS. Resistance to fluconazole and flucytosine is now sufficiently prevalent among Candida spp. isolated from patients with AIDS to warrant routine susceptibility testing of yeast isolates.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. J. Linton, A. M. Borman, G. Cheung, A. D. Holmes, A. Szekely, M. D. Palmer, P. D. Bridge, C. K. Campbell, and E. M. Johnson Molecular Identification of Unusual Pathogenic Yeast Isolates by Large Ribosomal Subunit Gene Sequencing: 2 Years of Experience at the United Kingdom Mycology Reference Laboratory J. Clin. Microbiol., April 1, 2007; 45(4): 1152 - 1158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Rognon, Z. Kozovska, A. T. Coste, G. Pardini, and D. Sanglard Identification of promoter elements responsible for the regulation of MDR1 from Candida albicans, a major facilitator transporter involved in azole resistance Microbiology, December 1, 2006; 152(12): 3701 - 3722. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Riggle and C. A. Kumamoto Transcriptional Regulation of MDR1, Encoding a Drug Efflux Determinant, in Fluconazole-Resistant Candida albicans Strains through an Mcm1p Binding Site Eukaryot. Cell, December 1, 2006; 5(12): 1957 - 1968. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.M. Coogan, P.L. Fidel Jr., M.C. Komesu, N. Maeda, and L.P. Samaranayake (B1) Candida and Mycotic Infections Advances in Dental Research, April 1, 2006; 19(1): 130 - 138. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. G. Playford, A. C. Webster, T. C. Sorrell, and J. C. Craig Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials J. Antimicrob. Chemother., April 1, 2006; 57(4): 628 - 638. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Harry, B. G. Oliver, J. L. Song, P. M. Silver, J. T. Little, J. Choiniere, and T. C. White Drug-Induced Regulation of the MDR1 Promoter in Candida albicans Antimicrob. Agents Chemother., July 1, 2005; 49(7): 2785 - 2792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kamai, M. Kakuta, T. Shibayama, T. Fukuoka, and S. Kuwahara Antifungal Activities of R-135853, a Sordarin Derivative, in Experimental Candidiasis in Mice Antimicrob. Agents Chemother., January 1, 2005; 49(1): 52 - 56. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Dodgson, C. Pujol, D. W. Denning, D. R. Soll, and A. J. Fox Multilocus Sequence Typing of Candida glabrata Reveals Geographically Enriched Clades J. Clin. Microbiol., December 1, 2003; 41(12): 5709 - 5717. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kamai, M. Kubota, T. Fukuoka, Y. Kamai, N. Maeda, T. Hosokawa, T. Shibayama, K. Uchida, H. Yamaguchi, and S. Kuwahara Efficacy of CS-758, a Novel Triazole, against Experimental Fluconazole-Resistant Oropharyngeal Candidiasis in Mice Antimicrob. Agents Chemother., February 1, 2003; 47(2): 601 - 606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. C. White, S. Holleman, F. Dy, L. F. Mirels, and D. A. Stevens Resistance Mechanisms in Clinical Isolates of Candida albicans Antimicrob. Agents Chemother., June 1, 2002; 46(6): 1704 - 1713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. R. Rustad, D. A. Stevens, M. A. Pfaller, and T. C. White Homozygosity at the Candida albicans MTL locus associated with azole resistance Microbiology, April 1, 2002; 148(4): 1061 - 1072. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Guthmiller, K. G. Vargas, R. Srikantha, L. L. Schomberg, P. L. Weistroffer, P. B. McCray Jr., and B. F. Tack Susceptibilities of Oral Bacteria and Yeast to Mammalian Cathelicidins Antimicrob. Agents Chemother., November 1, 2001; 45(11): 3216 - 3219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W. Henry, J. T. Nickels, and T. D. Edlind Upregulation of ERG Genes in Candida Species by Azoles and Other Sterol Biosynthesis Inhibitors Antimicrob. Agents Chemother., October 1, 2000; 44(10): 2693 - 2700. [Abstract] [Full Text]
|
|
|
|
|
|
K. Vargas, S. A. Messer, M. Pfaller, S. R. Lockhart, J. T. Stapleton, J. Hellstein, and D. R. Soll Elevated Phenotypic Switching and Drug Resistance of Candida albicans from Human Immunodeficiency Virus-Positive Individuals prior to First Thrush Episode J. Clin. Microbiol., October 1, 2000; 38(10): 3595 - 3607. [Abstract] [Full Text]
|
|
|
|
|
|
C. N. Lyons and T. C. White Transcriptional Analyses of Antifungal Drug Resistance in Candida albicans Antimicrob. Agents Chemother., September 1, 2000; 44(9): 2296 - 2303. [Abstract] [Full Text]
|
|
|
|
|
|
A. Cacciapuoti, D. Loebenberg, E. Corcoran, F. Menzel Jr., E. L. Moss Jr., C. Norris, M. Michalski, K. Raynor, J. Halpern, C. Mendrick, et al. In Vitro and In Vivo Activities of SCH 56592 (Posaconazole), a New Triazole Antifungal Agent, against Aspergillus and Candida Antimicrob. Agents Chemother., August 1, 2000; 44(8): 2017 - 2022. [Abstract] [Full Text]
|
|
|
|
|
|
S. Maesaki, M. A. Hossain, Y. Miyazaki, K. Tomono, T. Tashiro, and S. Kohno Efficacy of FK463, a (1,3)-beta -D-Glucan Synthase Inhibitor, in Disseminated Azole-Resistant Candida albicans Infection in Mice Antimicrob. Agents Chemother., June 1, 2000; 44(6): 1728 - 1730. [Abstract] [Full Text]
|
|
|
|
|
|
K. E. Miletti and M. J. Leibowitz Pentamidine Inhibition of Group I Intron Splicing in Candida albicans Correlates with Growth Inhibition Antimicrob. Agents Chemother., April 1, 2000; 44(4): 958 - 966. [Abstract] [Full Text]
|
|
|
|
|
|
H. Chang Chang, J. Jung Chang, A. Huey Huang, and T. Chain Chang Evaluation of a Capacitance Method for Direct Antifungal Susceptibility Testing of Yeasts in Positive Blood Cultures J. Clin. Microbiol., March 1, 2000; 38(3): 971 - 976. [Abstract] [Full Text]
|
|
|
|
|
|
D. C. Lamb, D. E. Kelly, T. C. White, and S. L. Kelly The R467K Amino Acid Substitution in Candida albicans Sterol 14alpha -Demethylase Causes Drug Resistance through Reduced Affinity Antimicrob. Agents Chemother., January 1, 2000; 44(1): 63 - 67. [Abstract] [Full Text]
|
|
|
|
|
|
B. Favre, M. Didmon, and N. S. Ryder Multiple amino acid substitutions in lanosterol 14{alpha}-demethylase contribute to azole resistance in Candida albicans Microbiology, October 1, 1999; 145(10): 2715 - 2725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Maesaki, P. Marichal, H. V. Bossche, D. Sanglard, and S. Kohno Rhodamine 6G efflux for the detection of CDR1-overexpressing azole-resistant Candida albicans strains J. Antimicrob. Chemother., July 1, 1999; 44(1): 27 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Lopez-Ribot, R. K. McAtee, S. Perea, W. R. Kirkpatrick, M. G. Rinaldi, and T. F. Patterson Multiple Resistant Phenotypes of Candida albicans Coexist during Episodes of Oropharyngeal Candidiasis in Human Immunodeficiency Virus-Infected Patients Antimicrob. Agents Chemother., July 1, 1999; 43(7): 1621 - 1630. [Abstract] [Full Text]
|
|
|
|
|
|
C. K. Campbell, K. G. Davey, A. D. Holmes, A. Szekely, and D. W. Warnock Comparison of the API Candida System with the AUXACOLOR System for Identification of Common Yeast Pathogens J. Clin. Microbiol., March 1, 1999; 37(3): 821 - 823. [Abstract] [Full Text]
|
|
|
|
|
|
F. S. Buckner, A. J. Wilson, T. C. White, and W. C. Van Voorhis Induction of Resistance to Azole Drugs in Trypanosoma cruzi Antimicrob. Agents Chemother., December 1, 1998; 42(12): 3245 - 3250. [Abstract] [Full Text]
|
|
|
|
|
|
S. De Wit, E. O'Doherty, J. Edwards, R. Yates, R. P. Smith, and A. N. Clumeck Pharmacokinetics of Two Multiple-Dosing Regimens of D0870 in Human Immunodeficiency Virus-Positive Patients: a Phase I Study Antimicrob. Agents Chemother., April 1, 1998; 42(4): 903 - 906. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. C. White, K. A. Marr, and R. A. Bowden Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance Clin. Microbiol. Rev., April 1, 1998; 11(2): 382 - 402. [Abstract] [Full Text] [PDF]
|
|